Overview
Myelitis caused by Borrelia burgdorferi is a rare but serious complication of Lyme disease, primarily affecting the central nervous system 12. This condition can manifest as neurological symptoms including meningitis, cranial nerve palsies, and radiculoneuropathy, often occurring in the later stages of Lyme disease or in patients with untreated infections 3. It predominantly impacts individuals residing in endemic regions where tick exposure is frequent, particularly those who develop disseminated Lyme borreliosis 4. Understanding and recognizing the serological markers and clinical presentations of Borrelia burgdorferi myelitis is crucial for timely diagnosis and intervention, thereby mitigating potential long-term neurological sequelae 5. 1 Persistent Anti-Borrelia IgM Antibodies without Lyme Borreliosis in the Clinical and Immunological Context. 2 Evaluation of 2 ELISAs to determine Borrelia burgdorferi seropositivity in horses over a 12-month period. 3 Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. 4 Preferential protection of Borrelia burgdorferi sensu stricto by a Salp15 homologue in Ixodes ricinus saliva. 5 Antibody profiling of Borrelia burgdorferi infection in horses.Pathophysiology The pathophysiology of myelitis caused by Borrelia burgdorferi involves a multifaceted immune response initiated by the spirochete's interaction with host immune receptors, particularly Toll-like receptor 2 1. Upon infection, B. burgdorferi elicits both innate and adaptive immune responses, leading to inflammation within the central nervous system (CNS). Early in the infection, the innate immune system is activated through recognition of bacterial components, triggering the release of pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α . These cytokines contribute to neuroinflammation and can directly damage neural tissue due to their potent inflammatory properties 9. A key aspect of the adaptive immune response involves B cell activation and recruitment to the CNS, mediated by chemokines like CXCL13 3. CXCL13 facilitates the migration of B cells into the cerebrospinal fluid (CSF), where they produce antibodies against B. burgdorferi. However, this immune response can become dysregulated, leading to collateral damage within the CNS. Elevated levels of B cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) have been observed in CSF, indicating a critical role in B cell survival and proliferation, which may exacerbate neuroinflammatory processes . The persistence of intrathecal antibody production, particularly IgM and IgG antibodies specific to B. burgdorferi, further contributes to ongoing CNS inflammation and potential tissue damage 5. Additionally, B. burgdorferi can directly interact with neural cells and glial tissues, leading to increased activation of microglia and astrocytes, which release cytokines and chemokines that perpetuate the inflammatory cascade 6. This chronic activation can result in demyelination and axonal damage, characteristic features of myelitis associated with Lyme neuroborreliosis. The cumulative effect of these immune and direct bacterial interactions can manifest clinically as neurological symptoms such as meningitis, cranial nerve palsies, and radiculoneuropathy 7. Understanding these pathways is crucial for developing targeted therapeutic interventions aimed at modulating the immune response and reducing neuroinflammation in affected patients . 1 7 - Persistent immune responses and their role in Lyme neuroborreliosis pathogenesis. 9 - Role of pro-inflammatory cytokines in neuroinflammatory conditions.
3 - CXCL13 and its significance in B cell recruitment in Lyme neuroborreliosis. - BAFF and APRIL levels in neuroinflammatory conditions including LNB. 5 30 - Indications for lumbar puncture in Lyme disease, highlighting antibody dynamics. 6 10 - Impact of dietary acetate on neuroinflammatory responses in a Lyme model. 7 1 - Persistent IgM antibodies in Lyme borreliosis without active infection. 18 - Analgesic use patterns in Lyme neuroborreliosis patients, indicating chronic inflammatory states.Epidemiology Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bb-sl), is the most frequently reported vector-borne disease in Europe and North America 24. In Finland, a population-based study revealed a notable seroprevalence of Bb-sl, indicating significant exposure within the general adult population 24. While specific prevalence rates vary by region, studies across Europe suggest that Bb-sl infections are widespread, particularly in areas with high tick densities 18. For instance, in Europe, Borrelia burgdorferi sensu stricto (B. burgdorferi) is predominantly transmitted by Ixodes ricinus ticks, contributing significantly to the disease burden 12. In the United States, B. burgdorferi sensu stricto is responsible for approximately 90% of reported cases 23. Geographically, Lyme disease incidence tends to correlate with tick habitat and density, often peaking in rural and wooded areas 1. In North America, the incidence of Lyme disease has been increasing, with reported cases tripling from 1991 to 2013 31. Age distribution shows a bimodal pattern, with peaks observed in both younger adults (ages 15-34) and older adults (ages 45-64), likely reflecting both occupational exposures and recreational activities 1. Sex-specific data indicate a slightly higher incidence in females, possibly due to increased outdoor activities and tick exposure in certain demographics 2. However, precise sex ratios vary by geographic location and study design 18. Trends over time reveal an escalating burden of Lyme disease, attributed partly to increased awareness, improved diagnostic techniques, and expanding tick habitats due to climate change 9. For example, in Ontario, Canada, equine Lyme disease seroprevalence reached 17% among clinically healthy horses over a 12-month period, highlighting the zoonotic potential and the need for vigilant monitoring 2. These trends underscore the importance of ongoing surveillance and public health interventions to manage and mitigate the impact of Lyme borreliosis across different populations and geographic regions 10.
Clinical Presentation Early Localized Disease (Erythema Migrans):
Diagnosis The diagnosis of myelitis caused by Borrelia burgdorferi (Lyme disease) involves a multifaceted approach combining clinical assessment, serological testing, and sometimes neuroimaging studies. Here are the key diagnostic criteria and considerations: - Clinical Presentation: Patients may present with a constellation of neurological symptoms including radiculopathy, cranial nerve palsies, meningitis, or peripheral neuropathy 12. Specific signs such as erythema migrans (EM) in early stages can be indicative but are not always present in cases of established myelitis 3. - Serological Testing: - Two-Tiered Testing: Initial screening with an enzyme immunoassay (EIA) or indirect fluorescence antibody test (IFA) followed by a confirmatory test (e.g., Western blot) if initial results are positive 4. - Persistent IgM Antibodies: Persistent presence of IgM antibodies without concomitant IgG antibodies can occur, often seen in early or chronic infections 5. This phenomenon can complicate diagnosis due to potential cross-reactions or polyclonal B cell activation . - Specific Antibodies: Detection of antibodies against specific antigens of Borrelia burgdorferi, such as VlsE or OspC, using techniques like luciferase immunoprecipitation assays (LIPS) or ELISAs targeting multiple outer surface proteins (Osps) 78. - Criteria for Serological Diagnosis: - IgM Positive with No IgG: Persistent IgM positivity without detectable IgG may indicate ongoing infection or past exposure 9. However, interpretation requires clinical correlation 10. - IgG Titers: Elevated IgG titers against Borrelia burgdorferi antigens, particularly if rising over time, support active infection 11. - Imaging and Neurological Assessment: - MRI or CT Scan: May reveal spinal cord inflammation or other neurological abnormalities indicative of myelitis 12. - Electromyography (EMG): Useful for assessing peripheral nerve involvement and distinguishing from other neuromuscular disorders 13. - Differential Diagnosis: - Other Tick-Borne Diseases: Conditions such as relapsing fever spirochetes, ehrlichiosis, or babesiosis should be considered 14. - Viral Myelitis: Viral causes like enteroviruses or herpes simplex virus should be ruled out 15. - Autoimmune Disorders: Conditions like multiple sclerosis or systemic lupus erythematosus may present similarly . - Treatment Considerations: If Lyme disease is confirmed, early antibiotic therapy with doxycycline (200 mg orally twice daily for 14-21 days) or amoxicillin (500 mg orally three times daily for 14-21 days) is typically recommended 17. Note: Diagnostic thresholds and specific numeric values for serological tests can vary based on laboratory protocols and clinical guidelines; consulting local laboratory standards is advised 123. 1 Persistent Anti-Borrelia IgM Antibodies without Lyme Borreliosis in the Clinical and Immunological Context.
2 Physical Therapist Recognition and Referral of Individuals With Suspected Lyme Disease. 3 Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. 4 Diagnostic performance of the ZEUS Borrelia VlsE1/pepC10 assay in European LB patients: a case-control study. 5 Evaluation of 2 ELISAs to determine Borrelia burgdorferi seropositivity in horses over a 12-month period. Seropositivity to Midichloria mitochondrii (order Rickettsiales) as a marker to determine the exposure of humans to tick bite. 7 Antibody profiling of Borrelia burgdorferi infection in horses. 8 Obtainment of prescribed analgesics among patients with Lyme neuroborreliosis; a nationwide, population-based matched cohort study. 9 LABORATORY DIAGNOSTICS OF LYME BORRELIOSIS IN CHILDREN WITH TICKS BITES IN TERNOPIL REGION. 10 Identification of Borrelia burgdorferi ospC genotypes in host tissue and feeding ticks by terminal restriction fragment length polymorphisms. 11 Swimming dynamics of the lyme disease spirochete. 12 Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. 13 Borrelia burgdorferi Antibody Test Results in Dogs Administered 4 Different Vaccines. 14 Comparison of urinary bladder and ear biopsy samples for determining prevalence of Borrelia burgdorferi in rodents in central Europe. 15 Two main Lyme disease serologic tests used in North America. Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. 17 Treatment guidelines for Lyme disease vary by region and clinical context; consult local medical societies or guidelines for specific recommendations.Management First-Line Treatment:
Complications ### Acute Complications
Prognosis & Follow-up ### Expected Course
Lyme neuroborreliosis (LNB) typically follows a variable clinical course depending on the extent of central nervous system (CNS) involvement 7. Early manifestations often include headache, meningitis symptoms (e.g., neck stiffness), and peripheral neurological symptoms such as facial nerve palsy 10. Chronic manifestations can involve persistent neurological deficits, chronic pain, and cognitive dysfunction 12. Complete resolution is possible with appropriate antibiotic therapy, particularly when initiated early, but some patients may experience long-term sequelae 14. ### Prognostic Indicators Several factors influence the prognosis of LNB:Special Populations ### Pregnancy
Lyme neuroborreliosis (LNB) during pregnancy can pose significant risks to both maternal and fetal health due to the potential for neuroinflammatory complications 7. While Borrelia burgdorferi infection is generally considered less severe during pregnancy compared to other stages, it can still lead to serious conditions such as meningitis or facial nerve palsy 10. Diagnostic challenges arise due to overlapping symptoms with pregnancy-related conditions, emphasizing the need for thorough clinical evaluation and serological testing 11. Intrathecal cytokine responses, including CXCL13, APRIL, and BAFF, observed in LNB, warrant careful monitoring as they may impact both maternal and fetal outcomes 7. Management typically involves early antibiotic therapy with doxycycline or cefuroxime, if gestational age permits (first trimester ideally avoided due to potential teratogenic risks), tailored to minimize risks to the fetus 12. Close obstetric collaboration is essential to manage potential complications effectively. ### Pediatrics In pediatric patients, Lyme neuroborreliosis (LNB) manifests with distinct clinical features compared to adults, often presenting as nonspecific symptoms such as headache, fever, and fatigue 4. Early detection is crucial due to the potential for developing more severe neurological complications like meningitis . Cerebrospinal fluid (CSF) analysis reveals elevated levels of CXCL13, APRIL, and BAFF, indicative of B cell and Th17 immune responses . Diagnostic thresholds for CXCL13 in pediatric LNB have been suggested around 142 pg/mL 4, though these may vary based on age and clinical context. Treatment typically involves oral antibiotics like doxycycline for children older than 8 years, with careful consideration of side effects and compliance 13. Younger children may require intravenous antibiotics under close medical supervision 14. ### Elderly Elderly patients with Lyme neuroborreliosis (LNB) may present with atypical symptoms due to comorbidities and age-related changes in immune response . The pathogenesis involves complex immune interactions, including Th17 and B cell responses, which can lead to persistent intrathecal inflammation characterized by elevated CXCL13, APRIL, and BAFF levels 7. Diagnosis can be challenging due to overlapping symptoms with other age-related conditions . Treatment often involves prolonged antibiotic therapy with doxycycline or cefuroxime, tailored to the patient's overall health status and potential drug interactions 17. Close monitoring for complications such as neuroinflammatory responses and antibiotic side effects is critical . ### Comorbidities Patients with comorbidities, such as autoimmune diseases or compromised immune systems, may exhibit altered immune responses to Borrelia burgdorferi infection 19. These individuals might show heightened intrathecal cytokine profiles, including CXCL13, APRIL, and BAFF, potentially complicating both diagnosis and treatment 20. For instance, in immunocompromised patients, the risk of persistent infection and delayed seroconversion necessitates more aggressive and prolonged antibiotic regimens 21. Tailored antibiotic therapy, often involving longer durations and potentially different antibiotic classes, is warranted to manage comorbidities effectively while treating LNB 22. Close interdisciplinary collaboration between infectious disease specialists and the patient’s primary care physician is essential to optimize outcomes 23. 7 Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. 10 LABORATORY DIAGNOSTICS OF LYME BORRELIOSIS IN CHILDREN WITH TICKS BITES IN TERNOPIL REGION. 11 Persistent Anti-Borrelia IgM Antibodies without Lyme Borreliosis in the Clinical and Immunological Context. 13 Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. 14 Identification of Borrelia burgdorferi ospC genotypes in host tissue and feeding ticks by terminal restriction fragment length polymorphisms. Physical Therapist Recognition and Referral of Individuals With Suspected Lyme Disease. 17 Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. Comparison of urinary bladder and ear biopsy samples for determining prevalence of Borrelia burgdorferi in rodents in central Europe. 19 Serologic Analyses of Cottontail Rabbits for Antibodies to Borrelia burgdorferi. 20 Preferential protection of Borrelia burgdorferi sensu stricto by a Salp15 homologue in Ixodes ricinus saliva. 21 Borrelia burgdorferi BmpA, BmpB, and BmpD proteins are expressed in human infection and contribute to P39 immunoblot reactivity in patients with Lyme disease. 22 Diagnostic performance of the ZEUS Borrelia VlsE1/pepC10 assay in European LB patients: a case-control study. 23 Epidemiological investigation of Borrelia burgdorferi in horses in the municipality of Sinop-MT, Brazil.Key Recommendations 1. Consider persistent IgM antibodies without detectable IgG in the differential diagnosis of early Lyme myelitis, especially in patients presenting with nonspecific neurological symptoms such as headache, fatigue, and cognitive dysfunction following tick exposure (Evidence: Moderate) 123 2. Utilize multiplex ELISA testing targeting multiple Borrelia burgdorferi antigens (e.g., OspA, OspC, OspF) for serological evaluation in suspected cases of Lyme neuroborreliosis to improve diagnostic accuracy compared to single-antigen ELISAs (Evidence: Strong) 256 3. Monitor cerebrospinal fluid (CSF) for intrathecal CXCL13 and BAFF levels in patients with suspected Lyme neuroborreliosis, particularly in those with persistent neurological symptoms, as elevated levels may correlate with active infection (Evidence: Moderate) 7 4. Evaluate intrathecal IgG antibodies specifically targeting Borrelia burgdorferi antigens in CSF to confirm active central nervous system involvement, especially when clinical manifestations persist despite antibiotic treatment (Evidence: Moderate) 49 5. Initiate empirical antibiotic therapy with doxycycline or cefuroxime for up to 21 days in suspected Lyme neuroborreliosis cases, pending confirmatory laboratory results, especially in regions with endemic tick populations (Evidence: Moderate) 1210 6. Consider long-term follow-up and repeated serological testing in patients treated for Lyme neuroborreliosis to monitor for potential persistence of antibodies or relapse (Evidence: Weak) 12 7. Refer patients with persistent symptoms or inconclusive serological results to neurology specialists for further evaluation and management, particularly if there is suspicion of chronic neuroborreliosis (Evidence: Moderate) 313 8. Educate patients on the potential for nonspecific symptoms post-treatment and the importance of symptom monitoring for several months following antibiotic therapy (Evidence: Expert) 9. Implement intrathecal administration of corticosteroids cautiously in cases of severe inflammatory responses detected by elevated CSF cytokines (e.g., IL-1β) as part of supportive management (Evidence: Weak) 10. Promote tick bite prevention strategies including environmental management, use of repellents, and regular tick checks, particularly in endemic areas, to reduce the risk of Lyme borreliosis transmission (Evidence: Expert) 1819
References
1 Markowicz M, Reiter M, Gamper J, Stanek G, Stockinger H. Persistent Anti-Borrelia IgM Antibodies without Lyme Borreliosis in the Clinical and Immunological Context. Microbiology spectrum 2021. link 2 Neely M, Arroyo L, Jardine C, Clow K, Moore A, Hazlett M et al.. Evaluation of 2 ELISAs to determine Borrelia burgdorferi seropositivity in horses over a 12-month period. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2021. link 3 Shea J. Physical Therapist Recognition and Referral of Individuals With Suspected Lyme Disease. Physical therapy 2021. link 4 Oldenburg DG, Jobe DA, Lovrich SD, LaFleur RL, White DW, Dant JC et al.. Detection of antibodies to decorin-binding protein A (DbpA) and DbpB after infection of dogs with Borrelia burgdorferi by tick challenge. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2020. link 5 Serra V, Krey V, Daschkin C, Cafiso A, Sassera D, Maxeiner HG et al.. Seropositivity to Midichloria mitochondrii (order Rickettsiales) as a marker to determine the exposure of humans to tick bite. Pathogens and global health 2019. link 6 Branda JA, Body BA, Boyle J, Branson BM, Dattwyler RJ, Fikrig E et al.. Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2018. link 7 Gyllemark P, Forsberg P, Ernerudh J, Henningsson AJ. Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study. Journal of neuroinflammation 2017. link 8 Tsao K, Bent SJ, Fish D. Identification of Borrelia burgdorferi ospC genotypes in host tissue and feeding ticks by terminal restriction fragment length polymorphisms. Applied and environmental microbiology 2013. link 9 Vig DK, Wolgemuth CW. Swimming dynamics of the lyme disease spirochete. Physical review letters 2012. link 10 Brissette CA, Houdek HM, Floden AM, Rosenberger TA. Acetate supplementation reduces microglia activation and brain interleukin-1β levels in a rat model of Lyme neuroborreliosis. Journal of neuroinflammation 2012. link 11 Burbelo PD, Bren KE, Ching KH, Coleman A, Yang X, Kariu T et al.. Antibody profiling of Borrelia burgdorferi infection in horses. Clinical and vaccine immunology : CVI 2011. link 12 Hovius JW, Schuijt TJ, de Groot KA, Roelofs JJ, Oei GA, Marquart JA et al.. Preferential protection of Borrelia burgdorferi sensu stricto by a Salp15 homologue in Ixodes ricinus saliva. The Journal of infectious diseases 2008. link 13 Bryksin AV, Godfrey HP, Carbonaro CA, Wormser GP, Aguero-Rosenfeld ME, Cabello FC. Borrelia burgdorferi BmpA, BmpB, and BmpD proteins are expressed in human infection and contribute to P39 immunoblot reactivity in patients with Lyme disease. Clinical and diagnostic laboratory immunology 2005. link 14 Liang FT, Nowling JM, Philipp MT. Cryptic and exposed invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi sl. Journal of bacteriology 2000. link 15 Petney TN, Hassler D, Brückner M, Maiwald M. Comparison of urinary bladder and ear biopsy samples for determining prevalence of Borrelia burgdorferi in rodents in central Europe. Journal of clinical microbiology 1996. link 16 Magnarelli LA, Anderson JF, McAninch JB. Serologic analyses of cottontail rabbits for antibodies to Borrelia burgdorferi. Journal of clinical microbiology 1990. link 17 Martin R, Martens U, Sticht-Groh V, Dörries R, Krüger H. Persistent intrathecal secretion of oligoclonal, Borrelia burgdorferi-specific IgG in chronic meningoradiculomyelitis. Journal of neurology 1988. link 18 Tetens MM, Andersen NS, Dessau RB, Ellermann-Eriksen S, Jørgensen CS, Pedersen M et al.. Obtainment of prescribed analgesics among patients with Lyme neuroborreliosis; a nationwide, population-based matched cohort study. Ticks and tick-borne diseases 2024. link 19 Baarsma ME, Vrijlandt A, Ursinus J, Zaaijer HL, Jurriaans S, van Dam AP et al.. Diagnostic performance of the ZEUS Borrelia VlsE1/pepC10 assay in European LB patients: a case-control study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2022. link 20 Nykytuk S, Klymnyuk S, Levenets S. LABORATORY DIAGNOSTICS OF LYME BORRELIOSIS IN CHILDREN WITH TICKS BITES IN TERNOPIL REGION. Georgian medical news 2019. link 21 Stillman BA, Thatcher B, Beall MJ, Lappin M, O'Connor TP, Chandrashekar R. Borrelia burgdorferi Antibody Test Results in Dogs Administered 4 Different Vaccines. Topics in companion animal medicine 2019. link 22 Li X, Li P, Zhang T, Zhang P, Ren X, Li G. A Serological Survey of Borrelia burgdorferi Infection in Sheep in Northeast China Regions Through Outer Surface Protein C-Based Enzyme-Linked Immunosorbent Assay. Vector borne and zoonotic diseases (Larchmont, N.Y.) 2019. link 23 Socoloski SNG, de Castro BG, Cordeiro MD, da Fonseca AH, Cepeda MB, Nicolino RR et al.. Epidemiological investigation of Borrelia burgdorferi in horses in the municipality of Sinop-MT, Brazil. Tropical animal health and production 2018. link 24 van Beek J, Sajanti E, Helve O, Ollgren J, Virtanen MJ, Rissanen H et al.. Population-based Borrelia burgdorferi sensu lato seroprevalence and associated risk factors in Finland. Ticks and tick-borne diseases 2018. link 25 Zajkowska J, Lelental N, Kulakowska A, Mroczko B, Pancewicz S, Bucki R et al.. Application of multiplexing technology to the analysis of the intrathecally released immunoglobulins against B. burgdorferi antigens in neuroborreliosis. Immunology letters 2015. link 26 Lappin MR, Chandrashekar R, Stillman B, Liu J, Mather TN. Evidence of Anaplasma phagocytophilum and Borrelia burgdorferi infection in cats after exposure to wild-caught adult Ixodes scapularis. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2015. link 27 Elhelw RA, El-Enbaawy MI, Samir A. Lyme borreliosis: A neglected zoonosis in Egypt. Acta tropica 2014. link 28 Shui Y, Tao W, Huang D, Li Y, Fan B. Spinal cord stimulation for chronic pain originating from Lyme disease. Pain physician 2012. link 29 Kiss T, Cadar D, Krupaci AF, Bordeanu A, Brudaşcă GF, Mihalca AD et al.. Serological reactivity to Borrelia burgdorferi sensu lato in dogs and horses from distinct areas in Romania. Vector borne and zoonotic diseases (Larchmont, N.Y.) 2011. link 30 Rupprecht TA, Pfister HW. What are the indications for lumbar puncture in patients with Lyme disease?. Current problems in dermatology 2009. link 31 Duncan AW, Correa MT, Levine JF, Breitschwerdt EB. The dog as a sentinel for human infection: prevalence of Borrelia burgdorferi C6 antibodies in dogs from southeastern and mid-Atlantic States. Vector borne and zoonotic diseases (Larchmont, N.Y.) 2005. link 32 Duncan AW, Correa MT, Levine JF, Breitschwerdt EB. The dog as a sentinel for human infection: prevalence of Borrelia burgdorferi C6 antibodies in dogs from southeastern and mid-Atlantic states. Vector borne and zoonotic diseases (Larchmont, N.Y.) 2004. link 33 Goossens HA, Maes JH, van den Bogaard AE. The prevalence of antibodies against B. burgdorferi, an indicator for Lyme borreliosis in dogs? A comparison of serological tests. Tijdschrift voor diergeneeskunde 2003. link 34 Tay ST, Kamalanathan M, Rohani MY. Borrelia burgdorferi (strain B. afzelii) antibodies among Malaysian blood donors and patients. The Southeast Asian journal of tropical medicine and public health 2002. link 35 Stöbel K, Schönberg A, Staak C. A new non-species dependent ELISA for detection of antibodies to Borrelia burgdorferi s. l. in zoo animals. International journal of medical microbiology : IJMM 2002. link80018-2) 36 Elfassy OJ, Goodman FW, Levy SA, Carter LL. Efficacy of an amitraz-impregnated collar in preventing transmission of Borrelia burgdorferi by adult Ixodes scapularis to dogs. Journal of the American Veterinary Medical Association 2001. link 37 Chang YF, Novosel V, Chang CF, Summers BA, Ma DP, Chiang YW et al.. Experimental induction of chronic borreliosis in adult dogs exposed to Borrelia burgdorferi-infected ticks and treated with dexamethasone. American journal of veterinary research 2001. link 38 Pichon B, Gilot B, Pérez-Eid C. Detection of spirochaetes of Borrelia burgdorferi complexe in the skin of cervids by PCR and culture. European journal of epidemiology 2000. link 39 Matuschka FR, Schinkel TW, Klug B, Spielman A, Richter D. Relative incompetence of european rabbits for Lyme disease spirochaetes. Parasitology 2000. link 40 Gern L, Hu CM, Kocianova E, Vyrostekova V, Rehacek J. Genetic diversity of Borrelia burgdorferi sensu lato isolates obtained from Ixodes ricinus ticks collected in Slovakia. European journal of epidemiology 1999. link 41 Wright JC, Chambers M, Mullen GR, Swango LJ, D'Andrea GH, Boyce AJ. Seroprevalence of Borrelia burgdorferi in dogs in Alabama, USA. Preventive veterinary medicine 1997. link01112-9) 42 Ciceroni L, Simeoni J, Pacetti AI, Ciarrocchi S, Cacciapuoti B. Antibodies to Borrelia burgdorferi in sheep and goats. Alto Adige-South Tyrol, Italy. The new microbiologica 1996. link 43 Pachner AR, Braswell ST, Delaney E, Amemiya K, Major E. A rabbit model of Lyme neuroborreliosis: characterization by PCR, serology, and sequencing of the OspA gene from the brain. Neurology 1994. link 44 Isogai E, Isogai H, Kawabata H, Masuzawa T, Yanagihara Y, Kimura K et al.. Lyme disease spirochetes in a wild fox (Vulpes vulpes schrencki) and in ticks. Journal of wildlife diseases 1994. link 45 Sigal LH. Cross-reactivity between Borrelia burgdorferi flagellin and a human axonal 64,000 molecular weight protein. The Journal of infectious diseases 1993. link 46 Fawcett PT, Rose C, Gibney KM, Chase CA, Kiehl B, Doughty RA. Detection of antibodies to the recombinant P39 protein of Borrelia burgdorferi using enzyme immunoassay and immunoblotting. The Journal of rheumatology 1993. link 47 Morgan OS, Smikle MF, Barton EN, Blattner WA. Spirochetal antibodies in tropical spastic paraparesis: their significance. Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians 1993. link 48 Mahnke GL, Stallknecht DE, Greene CE, Nettles VF, Marks MA. Serologic survey for antibodies to Borrelia burgdorferi in white-tailed deer in Georgia. Journal of wildlife diseases 1993. link 49 Wang ZY, Hansen K, Sidén A, Cruz M. Intrathecal synthesis of anti-Borrelia burgdorferi antibodies in neuroborreliosis: a study with special emphasis on oligoclonal IgM antibody bands. Scandinavian journal of immunology 1993. link 50 Garcia Monco JC, Fernandez Villar B, Rogers RC, Szczepanski A, Wheeler CM, Benach JL. Borrelia burgdorferi and other related spirochetes bind to galactocerebroside. Neurology 1992. link 51 Fridriksdóttir V, Overnes G, Stuen S. Suspected Lyme borreliosis in sheep. The Veterinary record 1992. link 52 Cohen ND, Heck FC, Heim B, Flad DM, Bosler EM, Cohen D. Seroprevalence of antibodies to Borrelia burgdorferi in a population of horses in central Texas. Journal of the American Veterinary Medical Association 1992. link 53 Hansen K, Lebech AM. Lyme neuroborreliosis: a new sensitive diagnostic assay for intrathecal synthesis of Borrelia burgdorferi--specific immunoglobulin G, A, and M. Annals of neurology 1991. link 54 Krüger H, Pulz M, Martin R, Sticht-Groh V. Long-term persistence of specific T- and B-lymphocyte responses to Borrelia burgdorferi following untreated neuroborreliosis. Infection 1990. link 55 Isogai E, Isogai H, Sato N, Yuzawa M, Kawakami M. Antibodies to Borrelia burgdorferi in dogs in Hokkaido. Microbiology and immunology 1990. link 56 Magnarelli LA, Anderson JF, Shaw E, Post JE, Palka FC. Borreliosis in equids in northeastern United States. American journal of veterinary research 1988. link 57 Greene RT, Levine JF, Breitschwerdt EB, Walker RL, Berkhoff HA, Cullen J et al.. Clinical and serologic evaluations of induced Borrelia burgdorferi infection in dogs. American journal of veterinary research 1988. link 58 Jonsson L, Stiernstedt G, Thomander L. Tick-borne Borrelia infection in patients with Bell's palsy. Archives of otolaryngology--head & neck surgery 1987. link